Recent Investment Analysts’ Ratings Updates for NuCana (NCNA)

Share on StockTwits

A number of firms have modified their ratings and price targets on shares of NuCana (NASDAQ: NCNA) recently:

  • 8/19/2019 – NuCana is now covered by analysts at HC Wainwright. They set a “buy” rating and a $20.00 price target on the stock. They wrote, “We have valued NuCana on a discounted cash flow (DCF) basis, which yields a $624M projected enterprise value as of mid-2020. Our calculations rely upon a 60% probability of approval for Acelarin across both front-line BTC and fourth-line 30% probability of approval for NUC-3373 in the mCRC indication. We utilize a 12% discount rate and 17% effective corporate income tax rate, along with a 1% terminal growth rate.””
  • 8/13/2019 – NuCana was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “
  • 8/10/2019 – NuCana was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $11.00 price target on the stock. According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “
  • 8/1/2019 – NuCana was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 7/31/2019 – NuCana was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 7/23/2019 – NuCana was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “
  • 7/9/2019 – NuCana was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 6/26/2019 – NuCana was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

NCNA traded down $1.26 during midday trading on Tuesday, hitting $6.06. The company had a trading volume of 7,420 shares, compared to its average volume of 15,823. The company has a market capitalization of $223.97 million, a PE ratio of -10.63 and a beta of 3.27. NuCana PLC has a twelve month low of $6.80 and a twelve month high of $30.10. The firm’s 50-day simple moving average is $9.20 and its 200-day simple moving average is $12.51.

Several hedge funds and other institutional investors have recently bought and sold shares of NCNA. Alps Advisors Inc. raised its holdings in shares of NuCana by 5.6% in the first quarter. Alps Advisors Inc. now owns 77,838 shares of the company’s stock valued at $1,323,000 after purchasing an additional 4,160 shares during the last quarter. Asymmetry Capital Management L.P. increased its holdings in NuCana by 5.4% during the first quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock worth $772,000 after buying an additional 2,346 shares during the last quarter. Marshall Wace North America L.P. increased its holdings in NuCana by 558.8% during the first quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock worth $1,034,000 after buying an additional 51,607 shares during the last quarter. Rothschild Investment Corp IL increased its holdings in NuCana by 126.1% during the second quarter. Rothschild Investment Corp IL now owns 28,075 shares of the company’s stock worth $291,000 after buying an additional 15,660 shares during the last quarter. Finally, Aperio Group LLC acquired a new position in NuCana during the second quarter worth $39,000. Institutional investors own 40.21% of the company’s stock.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.

See Also: Why is total return important?

Receive News & Ratings for NuCana PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Merit Medical Systems  PT Lowered to $40.00
Merit Medical Systems PT Lowered to $40.00
Gaming and Leisure Properties  Rating Increased to Hold at Zacks Investment Research
Gaming and Leisure Properties Rating Increased to Hold at Zacks Investment Research
Red River Bancshares  Stock Rating Lowered by Zacks Investment Research
Red River Bancshares Stock Rating Lowered by Zacks Investment Research
Ritter Pharmaceuticals  Downgraded to “Sell” at ValuEngine
Ritter Pharmaceuticals Downgraded to “Sell” at ValuEngine
Maxim Group Reaffirms “Hold” Rating for NXT-ID
Maxim Group Reaffirms “Hold” Rating for NXT-ID
BlackRock TCP Capital  Upgraded at BidaskClub
BlackRock TCP Capital Upgraded at BidaskClub


 
© 2006-2019 Zolmax.